AMPH
What one share of Amphastar Pharmaceuticals holds
Pharmaceutical Preparations
We are a biopharmaceutical company focusing on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as active pharmaceutical ingredient, or API products.
Amphastar Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $15.74 |
|---|---|
| Profit | $1.69 |
| Capex (buildings and equipment) | $0.68 |
| Free cash flow | $3.30 |
| Cash and investments | $5.26 |
| Debt | $14.39 |
| Book value | $18.06 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $5.37 | $0.21 | $0.45 | $0.36 | — | $7.12 |
| 2017 | $4.97 | $0.08 | $0.73 | $0.09 | — | $7.16 |
| 2018 | $6.35 | −$0.12 | $1.01 | −$0.19 | — | $7.13 |
| 2019 | $6.46 | $0.98 | $0.83 | $0.00 | — | $8.19 |
| 2020 | $7.12 | $0.03 | $0.69 | $0.48 | — | $8.47 |
| 2021 | $8.79 | $1.25 | $0.55 | $1.42 | — | $9.34 |
| 2022 | $9.52 | $1.74 | $0.46 | $1.24 | — | $10.99 |
| 2023 | $12.16 | $2.60 | $0.72 | $2.74 | — | $13.30 |
| 2024 | $14.06 | $3.06 | $0.79 | $3.31 | — | $15.38 |
| 2025 | $14.93 | $2.03 | $0.72 | $2.51 | — | $17.28 |